No Patient Left Behind
@nplb.bsky.social
We're a non-profit dedicated to making innovative medications affordable for everyone in America.
Patients want policies that lower their out-of-pocket costs without restricting access to the treatments they are prescribed—let’s listen to them.
Read the full findings here:
(4/4)
Read the full findings here:
(4/4)
Price Controls Hinder Treatment Access in Medicare Part D — No Patient Left Behind
A new survey demonstrates that a majority of consumers want health plans to lower out-of- pocket costs, but are concerned state government price controls will harm access and not reduce costs
nopatientleftbehind.org
March 12, 2025 at 6:55 PM
Patients want policies that lower their out-of-pocket costs without restricting access to the treatments they are prescribed—let’s listen to them.
Read the full findings here:
(4/4)
Read the full findings here:
(4/4)
Patients also fear broader impacts because of new policies:
85% worry that plans will withdraw from the market, limiting options.
(3/4)
85% worry that plans will withdraw from the market, limiting options.
(3/4)
March 12, 2025 at 6:55 PM
Patients also fear broader impacts because of new policies:
85% worry that plans will withdraw from the market, limiting options.
(3/4)
85% worry that plans will withdraw from the market, limiting options.
(3/4)
Of all respondents:
🚫 30% said their insurance denied them a doctor-prescribed drug in the past year, and 17% got no treatment at all.
💊 81% worry that the IRA will force them to switch from their prescribed medications.
💰 92% expect their out-of-pocket costs to increase.
(2/4)
🚫 30% said their insurance denied them a doctor-prescribed drug in the past year, and 17% got no treatment at all.
💊 81% worry that the IRA will force them to switch from their prescribed medications.
💰 92% expect their out-of-pocket costs to increase.
(2/4)
March 12, 2025 at 6:55 PM
Of all respondents:
🚫 30% said their insurance denied them a doctor-prescribed drug in the past year, and 17% got no treatment at all.
💊 81% worry that the IRA will force them to switch from their prescribed medications.
💰 92% expect their out-of-pocket costs to increase.
(2/4)
🚫 30% said their insurance denied them a doctor-prescribed drug in the past year, and 17% got no treatment at all.
💊 81% worry that the IRA will force them to switch from their prescribed medications.
💰 92% expect their out-of-pocket costs to increase.
(2/4)
It’s time for USTR to prioritize biopharmaceutical trade policy to ensure these treatments are affordable to patients who need them and allows innovation to continue.
February 18, 2025 at 10:54 PM
It’s time for USTR to prioritize biopharmaceutical trade policy to ensure these treatments are affordable to patients who need them and allows innovation to continue.
Other wealthy nations continue to undervalue the impact of life-saving medicines, paying far less for them while still benefiting from our scientific breakthroughs. These other wealthy countries, our trade competitors, don't have true markets for medicines.
February 18, 2025 at 10:54 PM
Other wealthy nations continue to undervalue the impact of life-saving medicines, paying far less for them while still benefiting from our scientific breakthroughs. These other wealthy countries, our trade competitors, don't have true markets for medicines.